Positive Phase 2 Trial Results for NP-G2-044 Presented at ASCO
Novita Pharmaceuticals, Inc. is excited to share promising updates from its Phase 2 clinical trial, focusing on NP-G2-044 while presenting at a prominent annual meeting. This innovative treatment demonstrates potential in combination with standard anti-PD-1 therapy for patients fighting advanced solid tumors resistant to previous treatments. The trial results, discussed in a presentation titled "Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy," showcase the therapeutic promise of NP-G2-044 in combating cancer metastasis and improving immune response.
Encouraging Safety and Efficacy Findings
Dr. Jillian Zhang, President & Chief Scientific Officer of Novita, highlighted their satisfaction with the ongoing positive data from the trial. She emphasized that these results underline the potential of their innovative fascin inhibitor to revolutionize treatments for patients with advanced and metastatic solid tumors. With favorable response rates noted, as well as the absence of new metastases in over half of the participants, there's a solid foundation to initiate a Phase 3 study evaluating NP-G2-044 combined with PLD in platinum-resistant ovarian cancer.
Trial Overview and Patient Data
Currently, 45 patients have been administered NP-G2-044, all of whom had previously progressed on anti-PD-1 therapies. With a median of two prior treatment lines, it’s significant that 20% had experienced four or more previous therapies. The selected dosing for NP-G2-044 in combination with anti-PD-1 therapy was 1600 mg QD, measured over four-week intervals. The primary aim of this trial was to determine the objective response rate (ORR), alongside secondary goals including progression-free survival, overall survival, and safety assessments.
Key Findings of the Phase 2 Trial
Here are some of the most notable findings from the trial:
- A Disease Control Rate of 76%, which incorporates patients with either Stable Disease or positive Objective Responses.
- The ORR stands at 21%, showcasing three patients achieving Partial Response and four attaining Complete Responses, with two patients exhibiting Pathologic Complete Responses.
- Durable responses and tumor control were observed across diverse cancer types, demonstrating the effectiveness for at least seven distinct malignancies.
- Notably, four patients are still receiving ongoing treatment, with two showing response durations exceeding 80 weeks in pancreatic and endometrial cancers.
- Impressively, 55% of participants did not develop new metastases during the study period.
- Significant clinical outcomes included sustained Complete Response in cervical cancer, target lesion CR in an endometrial patient, and clinical CRs in others.
Future Directions for Novita's Research
In response to the encouraging results, an amendment to the study is in progress, which aims to incorporate additional cohorts to further examine the effectiveness of NP-G2-044 with anti-PD-1 therapy across varied populations and tumor subtypes. Future analyses will aim to identify biomarkers for predicting responses and understanding resistance mechanisms, promoting personalized treatment approaches for patients facing treatment-resistant cancers. Novita is committed to advancing its research, with plans to reveal further data in the second half of the year and to commence enrollment in its pivotal Phase 3 study for NP-G2-044 + PLD in platinum-resistant ovarian cancer.
About Novita and Fascin Inhibitors
Novita Pharmaceuticals is striving to combat cancer metastasis, the leading cause of cancer-related mortality, by developing innovative fascin inhibitors. These inhibitors target a critical protein that facilitates tumor cell movement, which is overexpressed in tumor cells as well as in cells that present antigens within tumors. The company’s lead candidate, NP-G2-044, has shown a remarkable ability to suppress metastasis in both laboratory and clinical situations. It is also thought to enhance immune responses when combined with existing checkpoint inhibitors, thus providing a dual strategy against cancer.
About Novita Pharmaceuticals, Inc.
Novita Pharmaceuticals, Inc. focuses on pioneering biopharmaceuticals with an emphasis on preventing and treating cancer metastasis through innovative technologies. By advancing therapies that enhance immune responses alongside targeting cancer spread, Novita aims to address existing gaps in cancer treatment. For more information, visit the company's website.
Frequently Asked Questions
What is NP-G2-044?
NP-G2-044 is a fascin inhibitor developed by Novita Pharmaceuticals aimed at targeting metastasis in cancer treatment.
What were the main findings of the Phase 2 trial?
The trial reported a Disease Control Rate of 76%, with 21% achieving objective responses, including complete responses across various tumor types.
What future studies are planned for Novita's research?
Novita plans to expand the study, adding cohorts to evaluate the combination of NP-G2-044 with anti-PD-1 therapy, and explore biomarkers for better treatment predictions.
Who is leading Novita's clinical research?
Dr. Jillian Zhang serves as the President & Chief Scientific Officer, overseeing the research initiatives and the progress of NP-G2-044.
How does NP-G2-044 work in combination with other therapies?
It works by blocking metastasis while potentially enhancing immune responses against tumors when combined with immune checkpoint inhibitors.
